EUVIMEDEUVIMED entdecken
Crossref

Chimeric Tobramycin-Based Adjuvant TOB-TOB-CIP Potentiates Fluoroquinolone and β-Lactam Antibiotics against Multidrug-Resistant Pseudomonas aeruginosa

Shiv Dhiman, Danyel Ramirez, Yanqi Li, Ayush Kumar iD, Gilbert Arthur, Frank Schweizer iD

ACS Infectious Diseases · 2023

DOI: 10.1021/acsinfecdis.2c00549 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Infectious Diseases, 2023. Verfasst von Shiv Dhiman und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, University of Manitoba, Winnipeg R3T 2N2, Manitoba, Canada. Hauptthemen laut MEDLINE: Tobramycin, Ceftazidime. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 111 Literaturangaben. Gefördert von: CIHR, Institute of Infection and Immunity, Natural Sciences and Engineering Research Council of Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TobramycinCeftazidimePseudomonas aeruginosaFluoroquinolonesAztreonamAnti-Bacterial AgentsImipenemMonobactamsCiprofloxacinAdjuvants, PharmaceuticAzabicyclo Compounds

Stichwörter der Autor:innen

Pseudomonas aeruginosachimeric moleculesfluoroquinolonesouter membrane permeabilizerβ-lactamase inhibitorβ-lactams

Substanzen

TobramycinCeftazidimeFluoroquinolonesAztreonamAnti-Bacterial AgentsImipenemMonobactamsCiprofloxacinAdjuvants, Pharmaceuticavibactam

Autor:innen und Institutionen

  • Department of Chemistry, University of Manitoba, Winnipeg R3T 2N2, Manitoba, Canada.
  • Department of Microbiology, University of Manitoba, Winnipeg R3T 2N2, Manitoba, Canada.
  • Department of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg R3E 0J9, Manitoba, Canada.

ORCID-Profile: Ayush Kumar, Frank Schweizer

Förderung

  • CIHR
  • Institute of Infection and Immunity
  • Natural Sciences and Engineering Research Council of Canada

Zitieren

APA

Dhiman, S., Ramirez, D., Li, Y., Kumar, A., Arthur, G., & Schweizer, F. (2023). Chimeric Tobramycin-Based Adjuvant TOB-TOB-CIP Potentiates Fluoroquinolone and β-Lactam Antibiotics against Multidrug-Resistant Pseudomonas aeruginosa. ACS Infectious Diseases. https://doi.org/10.1021/acsinfecdis.2c00549

Vancouver

Dhiman S, Ramirez D, Li Y, Kumar A, Arthur G, Schweizer F. Chimeric Tobramycin-Based Adjuvant TOB-TOB-CIP Potentiates Fluoroquinolone and β-Lactam Antibiotics against Multidrug-Resistant Pseudomonas aeruginosa. ACS Infectious Diseases. 2023. doi:10.1021/acsinfecdis.2c00549

BibTeX
@article{Dhiman2023,
  author = {Dhiman, Shiv and Ramirez, Danyel and Li, Yanqi and Kumar, Ayush and Arthur, Gilbert and Schweizer, Frank},
  title = {Chimeric Tobramycin-Based Adjuvant TOB-TOB-CIP Potentiates Fluoroquinolone and β-Lactam Antibiotics against Multidrug-Resistant Pseudomonas aeruginosa},
  journal = {ACS Infectious Diseases},
  year = {2023},
  doi = {10.1021/acsinfecdis.2c00549}
}
Kostenlos starten →